Low-Affinity Anti-TfR Antibodies for Enhanced Brain Uptake

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current monoclonal antibodies targeting the blood-brain barrier (BBB) receptors have limited brain uptake due to high affinity, leading to rapid saturation and reduced distribution in the central nervous system (CNS), and may cause adverse effects such as reticulocyte depletion, necessitating the development of antibodies with reduced affinity and modified properties to enhance CNS penetration and safety.

Innovation Solution

Designing monoclonal antibodies with low affinity for the transferrin receptor (TfR) that specifically recognize both human and primate TfR, and modifying their effector functions, glycosylation, and complement activation capabilities to reduce adverse effects while maintaining effective CNS distribution, including pH-sensitive binding and co-administration of therapeutic agents to mitigate reticulocyte depletion.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If high-affinity antibodies are used to target BBB receptors, then receptor binding is improved, but brain uptake is limited due to rapid saturation

Engineering Contradiction:

Improvereceptor bindingVSAvoidbrain uptake

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent modifies the binding affinity parameter of the antibody to TfR from high to low affinity. This parameter change allows the antibody to avoid rapid saturation of BBB receptors while maintaining sufficient binding, thereby improving brain uptake and distribution without sacrificing reliable receptor interaction

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs low-affinity binding rather than high-affinity binding, which represents a partial action approach. This allows sufficient receptor engagement for transport while preventing excessive binding that would lead to rapid saturation and limited brain distribution

Inventive Principle:

Principle #16Partial or excessive action

2Reliability

If high-affinity antibodies are used to target BBB receptors, then receptor binding is improved, but distribution in CNS is reduced

Engineering Contradiction:

Improvereceptor bindingVSAvoidCNS distribution

Core Design Contradiction:

ReliabilityVSArea of stationary object

Solution Approach 1:

The patent changes the affinity parameter from high to low, enabling the antibody to distribute more widely throughout the CNS by avoiding rapid receptor saturation. This allows the antibody to reach broader CNS areas while maintaining reliable but not excessive receptor binding

Inventive Principle:

Principle #35Parameter changes

3Productivity

If traditional anti-BBB receptor antibodies are used, then BBB transport is achieved, but adverse effects such as reticulocyte depletion occur

Engineering Contradiction:

ImproveBBB transportVSAvoidreticulocyte depletion

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent modifies multiple parameters of the antibody including affinity for TfR, effector functions, and glycosylation patterns. These parameter changes enable effective BBB transport while reducing or eliminating adverse effects such as reticulocyte depletion by modulating the antibody's interaction with the immune system and red blood cells

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent modifies effector functions and glycosylation to convert potentially harmful immune activation into beneficial or neutral effects, allowing the antibody to perform BBB transport without causing reticulocyte depletion or other adverse immune-mediated effects

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

4Productivity

If low-affinity antibodies are used, then brain uptake is enhanced, but dosing frequency must be optimized to maintain therapeutic concentrations

Engineering Contradiction:

Improvebrain uptakeVSAvoidtherapeutic concentration duration

Core Design Contradiction:

ProductivityVSDuration of action of moving object

Solution Approach 1:

The patent modifies multiple parameters including affinity, effector functions, and glycosylation to achieve a balance where low affinity enhances brain uptake while the modified properties prolong therapeutic concentration duration, reducing dosing frequency requirements

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The low-affinity antibodies achieve enhanced brain uptake and prolonged therapeutic concentrations, reducing the frequency of dosing and minimizing side effects, while maintaining efficacy in transporting therapeutic compounds across the BBB for neurological disorders.

Implementation Method 1

Strategies to maximize brain uptake while minimizing reverse transcytosis back to the blood, and to also maximize the extent of accumulation after therapeutic dosing have been addressed with the finding that antibodies with low affinity to BBB receptors offer the potential to substantially increase BBB transport and CNS retention of associated therapeutic moieties/molecules

Methodology Applied

Scientific EffectReceptor-mediated transcytosis: